# Invesco CurrencyShares British Pound Sterling Trust: financial statements, quarterly

FXB · NYSE · CIK 1353611 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fxb.md) · [Financials](/companies/fxb/financials.md) · [Filings](/companies/fxb/filings.md) · [Insiders](/companies/fxb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fxb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [843](/filings/0000950170-24-122596.md) | [829 d](/filings/0000950170-25-027271.md) | [709](/filings/0000950170-25-067192.md) | [550](/filings/0000950170-25-105154.md) | [503](/filings/0001193125-25-270293.md) | [532 d](/filings/0001193125-26-083570.md) | [406](/filings/0001193125-26-209712.md) | [574](/filings/0001193125-26-338691.md) | [615](/filings/0001193125-25-270293.md) | [574 d](/filings/0001193125-26-083570.md) | [449](/filings/0001193125-26-209712.md) | [492](/filings/0001193125-26-338691.md) |
| Income tax | $k | [0.0 d](/filings/0000950170-23-060477.md) | [0.0 d](/filings/0000950170-24-019066.md) | [0.0](/filings/0000950170-24-054967.md) | [0.0 d](/filings/0000950170-24-092099.md) | [0.0 d](/filings/0000950170-24-122596.md) | [0.0 d](/filings/0000950170-25-027271.md) | [0.0](/filings/0000950170-25-067192.md) | [0.0 d](/filings/0000950170-25-105154.md) | [0.0 d](/filings/0001193125-25-270293.md) | not reported | [0.0](/filings/0001193125-26-209712.md) | [0.0 d](/filings/0001193125-26-338691.md) |
| Net income | $k | [748](/filings/0000950170-24-122596.md) | [738 d](/filings/0000950170-25-027271.md) | [632](/filings/0000950170-25-067192.md) | [490](/filings/0000950170-25-105154.md) | [446](/filings/0001193125-25-270293.md) | [469 d](/filings/0001193125-26-083570.md) | [354](/filings/0001193125-26-209712.md) | [496](/filings/0001193125-26-338691.md) | [525](/filings/0001193125-25-270293.md) | [487 d](/filings/0001193125-26-083570.md) | [376](/filings/0001193125-26-209712.md) | [412](/filings/0001193125-26-338691.md) |
| Diluted EPS | $ per share | [0.97](/filings/0000950170-24-122596.md) | not reported | [1.00](/filings/0000950170-25-067192.md) | [1.00](/filings/0000950170-25-105154.md) | [0.99](/filings/0001193125-25-270293.md) | not reported | [0.82](/filings/0001193125-26-209712.md) | [0.80](/filings/0001193125-26-338691.md) | [0.76](/filings/0001193125-25-270293.md) | not reported | [0.66](/filings/0001193125-26-209712.md) | [0.69](/filings/0001193125-26-338691.md) |
| Basic EPS | $ per share | [0.97](/filings/0000950170-24-122596.md) | not reported | [1.00](/filings/0000950170-25-067192.md) | [1.00](/filings/0000950170-25-105154.md) | [0.99](/filings/0001193125-25-270293.md) | not reported | [0.82](/filings/0001193125-26-209712.md) | [0.80](/filings/0001193125-26-338691.md) | [0.76](/filings/0001193125-25-270293.md) | not reported | [0.66](/filings/0001193125-26-209712.md) | [0.69](/filings/0001193125-26-338691.md) |

- Revenue: us-gaap:Revenues
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [93.8](/filings/0000950170-23-060477.md) | [85.7](/filings/0000950170-25-027271.md) | [66.7](/filings/0000950170-24-054967.md) | [54.6](/filings/0000950170-24-092099.md) | [64.4](/filings/0000950170-24-122596.md) | [60.2](/filings/0001193125-26-083570.md) | [55.8](/filings/0000950170-25-067192.md) | [92.1](/filings/0000950170-25-105154.md) | [84.1](/filings/0001193125-25-270293.md) | [77.5](/filings/0001193125-26-338691.md) | [82.3](/filings/0001193125-26-209712.md) | [76.5](/filings/0001193125-26-338691.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [94.1](/filings/0000950170-23-060477.md) | [86.0](/filings/0000950170-25-027271.md) | [73.0](/filings/0000950170-24-054967.md) | [54.8](/filings/0000950170-24-092099.md) | [64.6](/filings/0000950170-24-122596.md) | [60.3](/filings/0001193125-26-083570.md) | [55.9](/filings/0000950170-25-067192.md) | [92.4](/filings/0000950170-25-105154.md) | [84.3](/filings/0001193125-25-270293.md) | [84.3](/filings/0001193125-26-338691.md) | [82.5](/filings/0001193125-26-209712.md) | [76.7](/filings/0001193125-26-338691.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [0.0](/filings/0000950170-23-060477.md) | [0.0](/filings/0000950170-25-027271.md) | [6.1](/filings/0000950170-24-054967.md) | [0.0](/filings/0000950170-24-092099.md) | [0.0](/filings/0000950170-24-122596.md) | [0.0](/filings/0001193125-26-083570.md) | [0.0](/filings/0000950170-25-067192.md) | [0.0](/filings/0000950170-25-105154.md) | [0.0](/filings/0001193125-25-270293.md) | [6.7](/filings/0001193125-26-338691.md) | [0.0](/filings/0001193125-26-209712.md) | [0.0](/filings/0001193125-26-338691.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: not reported
- Total assets: us-gaap:Assets
- Current liabilities: not reported
- Total liabilities: us-gaap:Liabilities

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [722 d](/filings/0000950170-24-122596.md) | [748 d](/filings/0000950170-25-027271.md) | [688](/filings/0000950170-25-067192.md) | [531 d](/filings/0000950170-25-105154.md) | [451 d](/filings/0001193125-25-270293.md) | [471 d](/filings/0001193125-26-083570.md) | [376](/filings/0001193125-26-209712.md) | [444 d](/filings/0001193125-26-338691.md) | [536 d](/filings/0001193125-25-270293.md) | [517 d](/filings/0001193125-26-083570.md) | [384](/filings/0001193125-26-209712.md) | [410 d](/filings/0001193125-26-338691.md) |
| Dividends paid | $k | [729](/filings/0000950170-24-122596.md) | [690 d](/filings/0000950170-25-027271.md) | [646](/filings/0000950170-25-067192.md) | [514](/filings/0000950170-25-105154.md) | [431](/filings/0001193125-25-270293.md) | [468 d](/filings/0001193125-26-083570.md) | [362](/filings/0001193125-26-209712.md) | [487](/filings/0001193125-26-338691.md) | [550](/filings/0001193125-25-270293.md) | [492 d](/filings/0001193125-26-083570.md) | [393](/filings/0001193125-26-209712.md) | [425](/filings/0001193125-26-338691.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [970](/filings/0000950170-23-060477.md) | [968](/filings/0000950170-24-054967.md) | [860](/filings/0000950170-24-092099.md) | [771](/filings/0000950170-24-122596.md) | [634](/filings/0000950170-25-067192.md) | [491](/filings/0000950170-25-105154.md) | [452](/filings/0001193125-25-270293.md) | [431](/filings/0001193125-26-209712.md) | [616](/filings/0001193125-26-338691.md) | [686](/filings/0001193125-25-270293.md) | [571](/filings/0001193125-26-209712.md) | [601](/filings/0001193125-26-338691.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 600,000 at 2026-06-30, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-338691.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.